Oncology News | pharmaphorum

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

News

AbbVie, Genmab eye label expansion for Epkinly

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.

News

Nkarta tweaks regimen in bid to revive AML programme

Last year, Nkarta was celebrating data which showed that its natural killer (NK) cell therapy for acute myeloid leukaemia (AML) was showing remarkable efficacy in hard-to-

News

Study prompts call for ‘30th birthday’ screening tests

Routine screening at 30 for three genetic conditions that predispose to cancer and cardiovascular disease could save health services money, according to a recently publish

News

Swiss hospital adopts Bayer’s AI platform for radiology

A leading Swiss teaching hospital has signed up to use Bayer’s suite of artificial intelligence-powered digital tools for X-ray, MRI, and CT imaging.

News

Pfizer joins three-way PARP battle in prostate cancer

Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AbbVie, Genmab eye label expansion for Epkinly

Nkarta tweaks regimen in bid to revive AML programme

Study prompts call for ‘30th birthday’ screening tests

Swiss hospital adopts Bayer’s AI platform for radiology

Pfizer joins three-way PARP battle in prostate cancer

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks